If such mutations were to cause reduced MOMP as shown by us, sensitivity to cancer drugs operating through the mitochondrial pathway might be predicted to improve by adding a Bcl-2 inhibitor to the initial therapy. This evidence concerns the gene BCL2 and cancer.